Prostate Cancer - Oncotype DX Genomic Prostate Score (GPS) test

Oncotype DX Genomic Prostate Score® (GPSTM) test

Are you a candidate for active surveillance?

Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Exact Sciences will continue to perform the GPS test during the transition. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

You’ve been diagnosed with localized prostate cancer, so now what? You have treatment choices to make—starting with do you need treatment immediately? Your doctor has ordered the Oncotype DX Genomic Prostate Score (GPS) test to help you find out.

This short video explains how the GPS test analyzes the gene activity in your tumor to help gauge how likely it is to be aggressive and spread within the next 10 years.

Your prostate. Your decision.

Just as every patient is different, so is every prostate cancer tumor. The GPS test uses genomics to give you and your doctor important risk information about how your individual tumor will likely behave. Valuable insights include:

  • How aggressive your cancer is
  • How likely you are to die from your cancer within 10 years of surgery
  • How likely your cancer is to spread to other parts of your body (metastasis) within 10 years of surgery
Graphic Surveillance Surgery Radiation

Your GPS result can help you and your doctor determine what type of treatment is right for you based on your tumor’s characteristics.

Icon patient

 

More than 1.5 million breast, prostate, and colon cancer patients have relied on an Oncotype DX® test for insights that help guide their treatment decisions

The test provides crucial information, such as the aggressiveness of your tumor and predictive tumor behavior to help you make confident treatment decisions

Icon accurate


Risk estimates to help predict the benefit of surgery and radiation

Many localized prostate cancers are lower risk and not likely to be aggressive. They can be managed with active surveillance and regular doctor visits, thus delaying or completely avoiding the need for additional treatment

Icon guidelines

 

The GPS test is included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for prostate cancer

As a Category 2A molecular testing option for consideration in prostate cancer patients with low-risk and favorable intermediate-risk disease (life expectancy >10 years)

Is the GPS test right for you?

You may be a candidate for the GPS test if you have:

✔  Biopsy within 3 years
✔  Not started treatment
✔  Localized prostate cancer*

NOTE: If you’ve been diagnosed with late-stage metastatic castration-resistant prostate cancer (mCRPC), you may be eligible for the Oncotype DX AR-V7 Nucleus Detect® test.

Learn about the GPS testing process

What you can expect from the GPS results

In their own words: Stories  from patients with early-stage prostate cancer

See FAQs and videos  about the GPS test

89%
of GPS test patients have $0 financial responsibility

This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance. Your cost-sharing amounts, including deductibles and copays, will vary by plan and coverage type. Only your insurer can confirm if and how the GPS test will be covered.

94%
of GPS test patients have a financial responsibility of <$100

This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance. Patients with high-deductible plans may receive a bill for most or all of the cost of the GPS test if they have not satisfied their deductible.

*Excludes NCCN® very-high-risk prostate cancer.

†The numbers cited are based on historical patient billing data from 1/02/2021 to 12/31/2021. Rates of coverage vary by state and region. Exceptions for coverage may apply. Exact Sciences strongly encourages patients to contact their insurer with questions about the GPS test coverage.